Previous Close | 28.19 |
Open | 28.73 |
Bid | 30.07 x 700 |
Ask | 30.14 x 300 |
Day's Range | 28.50 - 30.38 |
52 Week Range | 24.43 - 46.35 |
Volume | 73,123 |
Avg. Volume | 102,266 |
Net Assets | 35M |
NAV | 31.82 |
PE Ratio (TTM) | N/A |
Yield | 0.00% |
YTD Return | -5.38% |
Beta (3y) | 0.00 |
Expense Ratio (net) | 0.95% |
Inception Date | 2015-06-22 |
Biotechnology and pharmaceutical ETFs have rallied in recent weeks as drug pricing concerns wane and investors look to the opportunity of this market segment. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) ...
Up more than 42% year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI ) , one of the largest biotechnology ETFs, is one of this year's best-performing non-leveraged ETFs. That does not mean XBI's run ...
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotechnology exchange traded fund by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca: XBI) have been soaring in ...
The SPDR S&P Biotech ETF (NYSEArca: XBI) , one of the largest biotechnology exchange traded funds, is getting in on the sector's resurgence. XBI, an equal-weight fund, is up about 7% over the past week, ...
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB ) , the largest biotechnology exchange traded fund by assets, is up nearly 18% and the behemoth biotech fund could add to those gains in September. ...
In 2Q17, Biogen’s (BIIB) net revenue from the sale of interferons amounted to ~$691 million, a 5% fall year-over-year (or YoY) and a ~7% rise quarter-over-quarter.
With names like AbbVie and Celgene on a tear the past week, many biotech sector ETFs hit 52-week or longer highs.